– Novel target for idiopathic pulmonary fibrosis was discovered using BenevolentAI’s AI-drug discovery platform and experimentally validated by AstraZeneca
– Announcement represents the second collaboration milestone following the addition of a novel chronic kidney disease target to AstraZeneca’s portfolio in Q1 2021
LONDON, Dec. 15, 2021 /PRNewswire/ — BenevolentAI, a leading clinical-stage AI drug discovery company, announced that AstraZeneca has added a novel target for idiopathic pulmonary fibrosis (IPF), discovered using BenevolentAI’s platform, to its drug development portfolio. This is the second novel target from the collaboration that has been identified, validated, and selected for AstraZeneca’s portfolio.
BenevolentAI’s strategic collaboration with AstraZeneca began in 2019, and currently focuses on discovering potential new treatments for IPF and chronic kidney disease (CKD). The innovative collaboration structure sees scientists and technologists from the two companies working side-by-side, combining the Benevolent Platform™ — an AI-driven drug discovery platform — and biomedical knowledge graph with AstraZeneca’s scientific expertise and rich datasets.
IPF is a chronic and ultimately fatal disease that causes lung tissue to stiffen, leading to permanent lung scarring that makes it harder to breathe. As IPF progresses, patients often need oxygen and, in some cases, lung transplantation. With a median survival of ∼3 years, the prognosis can be devastating, and there is a clear unmet need for better treatments.
Dr Anne Phelan, Chief Scientific Officer of BenevolentAI, commented, “The cause of IPF is largely unknown and the exact mechanisms involved in the progression of IPF remain elusive. Our collaboration uses advanced AI to enable expert scientists to navigate this challenging disease landscape, and discover novel targets with the potential to treat the underlying causes and prevent disease progression. This second, important milestone in our collaboration with AstraZeneca is further evidence of how our Platform can deliver tangible scientific results in the most complex therapeutic areas.”
Professor Maria Belvisi, SVP and Head of Research and Early Development, Respiratory and Immunology at AstraZeneca commented: “At AstraZeneca we aim to target the underlying disease drivers in Idiopathic Pulmonary Fibrosis (IPF) to stop fibrosis in its tracks, promote tissue regeneration and enable people with IPF to live life without limits. Our ongoing collaboration with BenevolentAI has enabled us to leverage the world’s available scientific literature and our in-house experiments, all brought together through machine learning to identify previously unrecognised links. I’m proud that this collaboration has delivered the first artificial intelligence driven IPF target to AstraZeneca’s portfolio.”
The strength of the collaboration was also recognised at the prestigious Scrip Awards in December 2021, where BenevolentAI and AstraZeneca won the ‘Best Partnership Alliance’ category. Notably, the award honours the industry’s highest-achieving partnerships, focusing on the most mutually beneficial, that have the most strategic potential and are most innovative in their structure.
BenevolentAI is a leading, clinical-stage AI drug discovery company. Through the combined capabilities of its AI platform, scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. BenevolentAI has a consistently proven track record of scientifically validated discoveries. The BenevolentAI Platform™ powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains successful commercial collaborations with leading pharmaceutical companies. BenevolentAI also identified Eli Lilly’s baricitinib as a repurposing drug candidate for COVID-19, which has been authorised for emergency use by the FDA. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.
Rajin Kang – VP Communications
The content is by PR NewsWire. DKODING Media is not responsible for the content provided or any links related to this content. DKODING Media is not responsible for the correctness, topicality or the quality of the content.